Modality
Small Molecule
MOA
GLP-1/GIP
Target
WRN
Pathway
Apoptosis
ALLDravetNASH
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ Feb 2031
Phase 1Current
NCT03470565
2,085 pts·ALL
2019-01→2031-02·Completed
NCT04759470
658 pts·Dravet
2021-12→2025-02·Terminated
2,743 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-131.1y agoPh2 Data· Dravet
2031-02-224.9y awayPh2 Data· ALL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1/2
Complet…
P1/2
Termina…
Catalysts
Ph2 Data
2025-02-13 · 1.1y ago
Dravet
Ph2 Data
2031-02-22 · 4.9y away
ALL
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03470565 | Phase 1/2 | ALL | Completed | 2085 | FEV1 |
| NCT04759470 | Phase 1/2 | Dravet | Terminated | 658 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| BEA-4274 | Beam | Phase 1/2 | ALK |